101495-34-5

Basic information

• Product Name: 4-nitrobenzo[d]oxazole-2-thiol
• Synonyms: 4-nitrobenzo[d]oxazole-2-thiol
• CAS NO: 101495-34-5
• Molecular Weight: 196.186
• Mol File: 101495-34-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 220 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• Boiling Point: 337.4±44.0 °C(Predicted)
• Density: 1.65±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-nitrobenzo[d]oxazole-2-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitrobenzo[d]oxazole-2-thiol(101495-34-5)
• EPA Substance Registry System: 4-nitrobenzo[d]oxazole-2-thiol(101495-34-5)

Safety Data

• Hazardous Substances Data: 101495-34-5(Hazardous Substances Data)

Upstream product

• 603-85-0 2-Amino-3-nitrophenol 
• 140-89-6 potassium ethyl xanthogenate 
• 463-71-8 thiophosgene 
• 75-15-0 carbon disulfide 

Downstream Products

• 959713-53-2 4-(4-nitrobenzoxazol-2-yl)piperazine-1-carboxylic acid benzyl ester 
• 213685-63-3 N-(2,6-diisopropylphenyl)-6-(4-aminobenzoxazol-2-ylthio)hexanamide 
• 213685-55-3 N-(2,6-diisopropylphenyl)-6-((4-nitrobenzo[d]oxazol-2-yl)thio)hexanamide 

Relevant articles and documents

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

Identification of a series of benzoxazoles as potent 5-HT6 ligands

As part of our continuing efforts to identify therapeutics for CNS diseases such as schizophrenia and Alzheimer's disease (AD), we have been focused on the 5-HT6 receptor in order to identify potent and selective ligands as a potential treatment for cognitive dysfunction. Herein we report the identification of a novel series of benzoxazole derivatives as potent 5-HT6 ligands. The synthesis and detailed SAR of this class of compounds are reported. The compounds have been shown to be full antagonists in a cyclic AMP functional assay.

BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES

This invention is concerned with compounds of the formula (I) wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical